293 related articles for article (PubMed ID: 15801997)
1. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
[TBL] [Abstract][Full Text] [Related]
2. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
3. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Malcolm C; Marrie TJ
Arch Intern Med; 2003 Apr; 163(7):797-802. PubMed ID: 12695270
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
6. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
9. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
[TBL] [Abstract][Full Text] [Related]
10. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
[TBL] [Abstract][Full Text] [Related]
11. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
12. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Griffin AT; Peyrani P; Wiemken T; Arnold F
Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
[TBL] [Abstract][Full Text] [Related]
13. [Treatment for Legionnaires' disease. Macrolides or quinolones?].
Falcó V; Molina I; Juste C; Crespo M; Almirante B; Pigrau C; Ferrer A; Bravo C; Palomar M; Pahissa A
Enferm Infecc Microbiol Clin; 2006; 24(6):360-4. PubMed ID: 16792936
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
[TBL] [Abstract][Full Text] [Related]
15. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
[TBL] [Abstract][Full Text] [Related]
16. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
[TBL] [Abstract][Full Text] [Related]
17. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
18. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
Wasserfallen JB; Erard V; Cometta A; Calandra T; Lamy O
Eur Respir J; 2004 Oct; 24(4):644-8. PubMed ID: 15459145
[TBL] [Abstract][Full Text] [Related]
20. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Mokabberi R; Haftbaradaran A; Ravakhah K
J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
